Market Cap 294.71M
Revenue (ttm) 40,000.00
Net Income (ttm) -274.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -686,125.05%
Debt to Equity Ratio 0.00
Volume 132,900
Avg Vol 103,670
Day's Range N/A - N/A
Shares Out 23.33M
Stochastic %K 39%
Beta -0.09
Analysts Strong Sell
Price Target $35.80

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which i...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 695 0677
Address:
201 Haskins Way, Suite 101, South San Francisco, United States
Peterson28
Peterson28 Jun. 16 at 2:27 PM
$LYEL Likely to hover around $10-$12 for a while, as MM accumulates enough positions before we see another pump.
0 · Reply
focafoca99
focafoca99 Jun. 12 at 5:15 PM
$LYEL exhibited new safety and translational data for its ronde-cel CAR‑T therapy at the EHA 2026 Congress.
0 · Reply
aletz
aletz Jun. 11 at 6:42 PM
$LYEL https://www.biostockinfo.com/biotech-catalyst-ai-scanner-june-wk3/ Picked as #5 pick this week from my AI Catalyst Scanner , Visit the link for more info. and catalyst driven investment ideas. Always do your own DD.
0 · Reply
terra987
terra987 Jun. 9 at 6:47 PM
$LYEL Sellers are gone?! Let's go to 100$ ... end of year.
0 · Reply
None_
None_ Jun. 9 at 12:35 AM
$LYEL https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/Lyell-Immunopharma-Provides-Update-on-Safety-Profile-of-LYL273-in-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer-and-Amends-Phase-1-Trial-to-Phase-1-2-Expansion.html
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 8 at 12:21 PM
$LYEL (-17.2% pre) Lyell amends colorectal cancer trial after reducing side effects - SI https://ooc.bz/l/104414
0 · Reply
Mdugs
Mdugs Jun. 2 at 9:11 PM
$LYEL oooooof
2 · Reply
MarketBeat
MarketBeat May. 27 at 8:04 AM
https://marketbeat.com/a/8676251/ $LYEL Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
0 · Reply
terra987
terra987 May. 21 at 10:38 AM
$LYEL Listened to the Stifel Forum talk: Lynn said (freely quoted!) "... J&J always wants to be the market leader; perhaps their technology has fallen behind, which is probably why they’ve discontinued their CD19/CD20 activities ... we’ve pursued a very aggressive strategy and it seems to be paying off ..." She came across as very convincing and I think everything is going according to plan so far. If the SP stays in the 17s some time or will even go lower I'll add even more.
0 · Reply
fantastex
fantastex May. 20 at 7:10 PM
$CRSR similar Pattern seen in $LYEL and $AMLX Pt $25
1 · Reply
Latest News on LYEL
Lyell Immunopharma Transcript: AGM 2026

Jun 10, 2026, 11:00 AM EDT - 14 days ago

Lyell Immunopharma Transcript: AGM 2026


Lyell Immunopharma Quarterly report: Q1 2026

May 6, 2026, 4:00 PM EDT - 7 weeks ago

Lyell Immunopharma Quarterly report: Q1 2026


Lyell Immunopharma Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 7 weeks ago

Lyell Immunopharma Earnings release: Q1 2026


Lyell Immunopharma initiated with an Outperform at Baird

2026-04-30T20:51:07.000Z - 7 weeks ago

Lyell Immunopharma initiated with an Outperform at Baird


Lyell Immunopharma Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Lyell Immunopharma Proxy statement: Proxy filing


Lyell Immunopharma Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Lyell Immunopharma Proxy statement: Proxy filing


Lyell Immunopharma initiated with a Buy at Needham

2026-04-10T10:06:03.000Z - 2 months ago

Lyell Immunopharma initiated with a Buy at Needham


Lyell Immunopharma Registration statement: Registration filing

Apr 3, 2026, 8:00 AM EDT - 2 months ago

Lyell Immunopharma Registration statement: Registration filing


Lyell Immunopharma Annual report: Q4 2025

Mar 12, 2026, 4:00 PM EDT - 3 months ago

Lyell Immunopharma Annual report: Q4 2025


Lyell Immunopharma Earnings release: Q4 2025

Mar 12, 2026, 4:00 PM EDT - 3 months ago

Lyell Immunopharma Earnings release: Q4 2025


Lyell Immunopharma appoints Smital Shah as CFBO

2026-03-09T12:15:08.000Z - 3 months ago

Lyell Immunopharma appoints Smital Shah as CFBO


Lyell Immunopharma initiated with an Outperform at Citizens

2026-03-09T08:50:14.000Z - 3 months ago

Lyell Immunopharma initiated with an Outperform at Citizens


Lyell Immunopharma Slides: Company presentation

Jan 23, 2026, 7:00 AM EST - 5 months ago

Lyell Immunopharma Slides: Company presentation


Lyell Immunopharma trading resumes

2025-12-22T17:15:21.000Z - 6 months ago

Lyell Immunopharma trading resumes


Lyell Immunopharma trading halted, volatility trading pause

2025-12-22T17:05:33.000Z - 6 months ago

Lyell Immunopharma trading halted, volatility trading pause


Lyell Immunopharma Transcript: Study Update

Dec 8, 2025, 8:30 AM EST - 7 months ago

Lyell Immunopharma Transcript: Study Update


Lyell Immunopharma Press release: Study Update

Dec 8, 2025, 8:30 AM EST - 7 months ago

Lyell Immunopharma Press release: Study Update


Lyell Immunopharma Slides: Study Update

Dec 8, 2025, 8:30 AM EST - 7 months ago

Lyell Immunopharma Slides: Study Update


Lyell Immunopharma Registration statement: Registration Filing

Dec 5, 2025, 7:00 AM EST - 7 months ago

Lyell Immunopharma Registration statement: Registration Filing


Lyell Immunopharma reports Q3 revenue $15k vs $34k last year

2025-11-12T21:32:17.000Z - 8 months ago

Lyell Immunopharma reports Q3 revenue $15k vs $34k last year


Lyell Immunopharma Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Lyell Immunopharma Earnings release: Q3 2025


Lyell Immunopharma Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Lyell Immunopharma Quarterly report: Q3 2025


Lyell Immunopharma Transcript: Investor Update

Nov 10, 2025, 8:30 AM EST - 8 months ago

Lyell Immunopharma Transcript: Investor Update


Lyell Immunopharma Press release: Investor Update

Nov 10, 2025, 8:30 AM EST - 8 months ago

Lyell Immunopharma Press release: Investor Update


Lyell Immunopharma Slides: Investor Update

Nov 10, 2025, 8:30 AM EST - 8 months ago

Lyell Immunopharma Slides: Investor Update


Lyell Immunopharma acquires exclusive global rights to LYL273

2025-11-10T13:01:16.000Z - 8 months ago

Lyell Immunopharma acquires exclusive global rights to LYL273


Lyell Immunopharma initiated with a Buy at Lucid Capital

2025-09-26T11:15:10.000Z - 9 months ago

Lyell Immunopharma initiated with a Buy at Lucid Capital


Lyell Immunopharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Lyell Immunopharma Quarterly report: Q2 2025


Lyell Immunopharma Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Lyell Immunopharma Earnings release: Q2 2025


Lyell Immunopharma Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Lyell Immunopharma Registration statement: Registration Filing


Lyell Immunopharma Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Quarterly report: Q1 2025


Lyell Immunopharma Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Earnings release: Q1 2025


Lyell Immunopharma Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Proxy statement: Proxy Filing


Lyell Immunopharma Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Proxy statement: Proxy Filing


Lyell Immunopharma Annual report: Q4 2024

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Annual report: Q4 2024


Lyell Immunopharma Earnings release: Q4 2024

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Earnings release: Q4 2024


Lyell Immunopharma Slides: FY 2025

Jan 15, 2025, 12:00 PM EST - 1 year ago

Lyell Immunopharma Slides: FY 2025


Lyell Immunopharma Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Lyell Immunopharma Earnings release: Q3 2024


Lyell Immunopharma Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Lyell Immunopharma Quarterly report: Q3 2024


Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio


Lyell Immunopharma Transcript: M&A Announcement

Oct 24, 2024, 4:30 PM EDT - 1 year ago

Lyell Immunopharma Transcript: M&A Announcement


Lyell Immunopharma Press release: M&A Announcement

Oct 24, 2024, 4:30 PM EDT - 1 year ago

Lyell Immunopharma Press release: M&A Announcement


Lyell Immunopharma Slides: M&A Announcement

Oct 24, 2024, 4:30 PM EDT - 1 year ago

Lyell Immunopharma Slides: M&A Announcement


Lyell Immunopharma Quarterly report: Q2 2024

Aug 7, 2024, 4:00 PM EDT - 2 years ago

Lyell Immunopharma Quarterly report: Q2 2024


Lyell Immunopharma Earnings release: Q2 2024

Aug 7, 2024, 4:00 PM EDT - 2 years ago

Lyell Immunopharma Earnings release: Q2 2024


Lyell Immunopharma Transcript: Study Update

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Lyell Immunopharma Transcript: Study Update


Lyell Immunopharma Press release: Study Update

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Lyell Immunopharma Press release: Study Update


Lyell Immunopharma Slides: Study Update

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Lyell Immunopharma Slides: Study Update


Lyell Immunopharma Quarterly report: Q1 2024

May 6, 2024, 7:30 AM EDT - 2 years ago

Lyell Immunopharma Quarterly report: Q1 2024


Lyell Immunopharma Earnings release: Q1 2024

May 6, 2024, 7:30 AM EDT - 2 years ago

Lyell Immunopharma Earnings release: Q1 2024


Lyell Immunopharma Slides: Q1 2024

May 6, 2024, 7:30 AM EDT - 2 years ago

Lyell Immunopharma Slides: Q1 2024


Lyell Immunopharma Proxy statement: Proxy Filing

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Lyell Immunopharma Proxy statement: Proxy Filing


Lyell Immunopharma Proxy statement: Proxy Filing

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Lyell Immunopharma Proxy statement: Proxy Filing


Lyell Immunopharma Registration statement: Registration Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

Lyell Immunopharma Registration statement: Registration Filing


Lyell Immunopharma Annual report: Q4 2023

Feb 28, 2024, 4:00 PM EST - 2 years ago

Lyell Immunopharma Annual report: Q4 2023


Lyell Immunopharma Earnings release: Q4 2023

Feb 28, 2024, 4:00 PM EST - 2 years ago

Lyell Immunopharma Earnings release: Q4 2023


Lyell Immunopharma Slides: FY 2024

Jan 10, 2024, 11:15 AM EST - 2 years ago

Lyell Immunopharma Slides: FY 2024


Lyell Immunopharma Quarterly report: Q3 2023

Nov 7, 2023, 4:00 PM EST - 2 years ago

Lyell Immunopharma Quarterly report: Q3 2023


Lyell Immunopharma Earnings release: Q3 2023

Nov 7, 2023, 4:00 PM EST - 2 years ago

Lyell Immunopharma Earnings release: Q3 2023


Lyell Immunopharma Quarterly report: Q2 2023

Aug 8, 2023, 4:00 PM EDT - 3 years ago

Lyell Immunopharma Quarterly report: Q2 2023


Lyell Immunopharma Earnings release: Q2 2023

Aug 8, 2023, 4:00 PM EDT - 3 years ago

Lyell Immunopharma Earnings release: Q2 2023


Peterson28
Peterson28 Jun. 16 at 2:27 PM
$LYEL Likely to hover around $10-$12 for a while, as MM accumulates enough positions before we see another pump.
0 · Reply
focafoca99
focafoca99 Jun. 12 at 5:15 PM
$LYEL exhibited new safety and translational data for its ronde-cel CAR‑T therapy at the EHA 2026 Congress.
0 · Reply
aletz
aletz Jun. 11 at 6:42 PM
$LYEL https://www.biostockinfo.com/biotech-catalyst-ai-scanner-june-wk3/ Picked as #5 pick this week from my AI Catalyst Scanner , Visit the link for more info. and catalyst driven investment ideas. Always do your own DD.
0 · Reply
terra987
terra987 Jun. 9 at 6:47 PM
$LYEL Sellers are gone?! Let's go to 100$ ... end of year.
0 · Reply
None_
None_ Jun. 9 at 12:35 AM
$LYEL https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/Lyell-Immunopharma-Provides-Update-on-Safety-Profile-of-LYL273-in-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer-and-Amends-Phase-1-Trial-to-Phase-1-2-Expansion.html
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 8 at 12:21 PM
$LYEL (-17.2% pre) Lyell amends colorectal cancer trial after reducing side effects - SI https://ooc.bz/l/104414
0 · Reply
Mdugs
Mdugs Jun. 2 at 9:11 PM
$LYEL oooooof
2 · Reply
MarketBeat
MarketBeat May. 27 at 8:04 AM
https://marketbeat.com/a/8676251/ $LYEL Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
0 · Reply
terra987
terra987 May. 21 at 10:38 AM
$LYEL Listened to the Stifel Forum talk: Lynn said (freely quoted!) "... J&J always wants to be the market leader; perhaps their technology has fallen behind, which is probably why they’ve discontinued their CD19/CD20 activities ... we’ve pursued a very aggressive strategy and it seems to be paying off ..." She came across as very convincing and I think everything is going according to plan so far. If the SP stays in the 17s some time or will even go lower I'll add even more.
0 · Reply
fantastex
fantastex May. 20 at 7:10 PM
$CRSR similar Pattern seen in $LYEL and $AMLX Pt $25
1 · Reply
Biocontrol
Biocontrol May. 19 at 3:32 PM
$LYEL J&J should buy this up to reboot their CAR 19/20 aspirations. Lynn is impressive.
1 · Reply
Mdugs
Mdugs May. 14 at 8:30 PM
$LYEL what’s up here
1 · Reply
MorganHoratio
MorganHoratio May. 8 at 1:36 PM
Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $HYPR - 898,720 $LYEL - 293,256 $MAZE - 1,388,583 $GLUE - 684,275 $OSCR - 481,988 Google's Q1 13F reveals a sharp focus: Cybersecurity Bedrock + AI Bio-Engineering! The stake in $HYPR is a massive signal—in a 2026 defined by AI deepfakes, Google is leaning on $HYPR's passwordless tech to fortify its Gemini ecosystem. Meanwhile, the heavy lifting in $MAZE and $GLUE proves Alphabet is no longer just indexing information, but indexing "cures" through AI-led protein modeling. With $OSCR hitting its profitability inflection point, do you think Google is just building an AI-health moat, or are we looking at the early days of its next multi-billion dollar "Other Bet" breakout? Let's discuss your top small-cap pick!
3 · Reply
Multiplyme7x
Multiplyme7x Apr. 25 at 12:28 PM
$XLO this is the same set up at $STRO stayed below $1 for many months then had a reverse split a few months after the split started going up now its above $30 check them out , $VOR and $LYEL also had reverse splits and headed north after a few months of nothing .
0 · Reply
Quantumup
Quantumup Apr. 22 at 2:06 PM
William Blair reiterated $KYTX at an Outperform rating. $CABA $LYEL RNAC RHHBY JNJ ARGX REGN IMVT NVS Here's what William Blair said in its note to investors: https://x.com/Quantumup1/status/2046953004239110438?s=20
0 · Reply
terra987
terra987 Apr. 9 at 3:10 PM
$LYEL Some buyers seem to know something, especially regarding the H2H-Pivotal results? 20 SMA broken - that's nice. If the interim data mid/end 2026 are good I'll not sell below 100$.
1 · Reply
focafoca99
focafoca99 Apr. 7 at 9:32 PM
$LYEL is only announcing participation in Needham's virtual healthcare conference on April 14.
0 · Reply
Mdugs
Mdugs Apr. 7 at 6:05 PM
$LYEL closing here or above would be nice.
0 · Reply
Hopipaytrader
Hopipaytrader Mar. 24 at 4:59 PM
$LYEL 200 dma magnet
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 24 at 3:58 PM
$LYEL Share Price: $19.54 Contract Selected: Jul 17, 2026 $20 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.14 – $2.62 Potential Upside: 59% ROI Time to Expiration: 114 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
terra987
terra987 Mar. 23 at 2:57 PM
$LYEL 13$ - wishful thinking
0 · Reply